Analyst Research
| Report Title | Price |
|---|---|
|
Provider: News Bites Pty Limited
|
$5.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: News Bites Pty Limited
|
$5.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cipla Ltd Updates On FY 2013 Guidance-Conference Call
Cipla Ltd announced that for fiscal 2013 top line guidance, the Company had said it would be about 12% to 15% and now expects it will be about in excess of 15%. EBITDA has gone up and the Company expects much better than what it was in fiscal 2012. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $81.054 billion and EBITDA of $19.805 billion for fiscal 2013.
Latest Key Developments in Pharmaceuticals
- Nattopharma ASA Maintains FY 2013 Revenue Guidance
- Grifols SA’s Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency-DJ
- Protalex Inc Announces Positive Interim Review of Phase 1b Trial Of PRTX-100 in Rheumatoid Arthritis By Independent Data Safety Monitoring Committee
- Pfizer Inc Announces Plan For Split-Off Of Zoetis Inc
- Share this
- Link this
- Digg this
Follow Reuters